{"id":"NCT01045707","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","officialTitle":"NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2010-01-11","resultsPosted":"2015-11-20","lastUpdate":"2016-12-08"},"enrollment":530,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec/insulin aspart","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDegAsp OD","type":"EXPERIMENTAL"},{"label":"IGlar OD","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both as add-on to subject's ongoing treatment with metformin + at least one OAD (oral anti-diabetic drug).\n\nThe main period is registered internally at Novo Nordisk as NN5401-3590 while the extension period is registered as NN5401-3726.","primaryOutcome":{"measure":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDegAsp OD","deltaMin":-1.65,"sd":1.28},{"arm":"IGlar OD","deltaMin":-1.72,"sd":1.17}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":92,"countries":["United States","Austria","India","Poland","Puerto Rico","Russia","South Korea","Spain","Turkey (Türkiye)"]},"refs":{"pmids":["27760129","35044568"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":265},"commonTop":["Nasopharyngitis","Hypertension","Diarrhoea","Headache","Back Pain"]}}